Semaglutide vs Tirzepatide: A Clear GLP-1 Agonist Comparison

By Theo Marcell (editorial pen name) · Updated September 30, 2026 · We may have a financial affiliation with some entities featured on this page.

The short answer: Semaglutide activates one gut-hormone receptor (GLP-1); tirzepatide activates two (GIP and GLP-1). Both are once-weekly injectables sold under different brand names for different labeled uses. In the SURMOUNT-5 trial of 751 adults with obesity but without type 2 diabetes, average weight loss at 72 weeks was greater with tirzepatide. Individual results vary.

If you’re comparing semaglutide and tirzepatide, you probably want plain answers rather than a list of programs. How do they work? Which brand names contain which molecule? What did head-to-head trials actually find? This guide covers those questions. It’s educational and isn’t medical advice. Whether either medicine fits you is a conversation for a clinician who knows your history, labs, other medications, and goals.

How do semaglutide and tirzepatide work differently?

Both belong to the incretin-based family of medicines, which act on gut-hormone pathways involved in appetite, fullness, and blood sugar. Both are used alongside changes in diet and physical activity.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released after eating. According to its prescribing information, it stimulates insulin release and lowers glucagon in a glucose-dependent way, slows stomach emptying, and reduces calorie intake, likely by acting on appetite.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates the GLP-1 receptor and also the receptor for glucose-dependent insulinotropic polypeptide (GIP), a second incretin hormone. Educators often describe it as working on two related pathways instead of one.

That dual design is the main mechanistic difference. It helps explain why the two drugs produced different average outcomes in trials, and why their side-effect patterns look similar without being identical. It doesn’t predict how any one person will respond.

Which brands contain which drug, and what are they approved for?

The same active ingredient can carry different brand names with different labeled uses. The table below is a high-level map, checked against current FDA prescribing information on DailyMed as of September 2026. Labels change, so confirm details against the current prescribing information for the exact product.

Active ingredient	Brand (form)	Labeled uses as of September 2026 (high level)
Semaglutide	Ozempic (weekly injection)	Injection: improving blood sugar control in adults with type 2 diabetes (with diet and exercise); reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. (Not a weight-management label.)
Semaglutide	Wegovy (weekly injection; daily tablet)	Injection: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; long-term weight reduction in adults and in children 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults, under accelerated approval based on improvement of MASH and fibrosis, so continued approval may depend on a confirmatory trial. Tablets: cardiovascular risk reduction and long-term weight reduction in adults, with the same conditions as the injection.
Semaglutide	Rybelsus (daily tablet)	Tablets: improving blood sugar control in adults with type 2 diabetes (with diet and exercise); reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them. The current label is shared with a newer tablet also branded Ozempic, and the two are not substitutable milligram for milligram.
Tirzepatide	Mounjaro (weekly injection)	Improving blood sugar control in adults and children 10 and older with type 2 diabetes (with diet and exercise). Check the current label for any additional indications.
Tirzepatide	Zepbound (weekly injection)	With a reduced-calorie diet and more physical activity: reducing excess body weight and maintaining the reduction long term in adults with obesity, or with overweight plus at least one weight-related condition; treating moderate to severe obstructive sleep apnea in adults with obesity.

A few rules save a lot of confusion:

Ozempic and Wegovy both contain semaglutide, but they’re separate products with separate labels. Our explainer on how Wegovy and Ozempic differ despite sharing a molecule goes deeper.
Mounjaro and Zepbound both contain tirzepatide, with different labeled uses. See what’s actually different between Zepbound and Mounjaro.
Searches like “Mounjaro vs Ozempic” or “Wegovy vs Zepbound” are really semaglutide-vs-tirzepatide questions, filtered through a specific diagnosis and coverage situation.

How are they taken? What the labels say about dosing

This section is about reading the label, not choosing a dose.

Frequency: The injectable brands (Ozempic, Wegovy injection, Mounjaro, Zepbound) are typically once-weekly injections. Semaglutide also comes as once-daily tablets (Rybelsus, and Wegovy tablets as of the current label), which have their own instructions about timing, water, and food.
Gradual increases: The prescribing information for each product describes starting at a low dose and increasing gradually over several weeks. The labels say this step-up is meant to reduce the risk of gastrointestinal side effects. Your clinician determines the dose, including whether and when to change it.
Brand-specific details: Each brand’s label sets its own dose strengths, maintenance ranges, and missed-dose rules. Those details differ between products, even between two brands that contain the same molecule, so they aren’t interchangeable. The Medication Guide and Instructions for Use for the exact product are the reference, and a pharmacist can walk you through them.

What do head-to-head trials show?

Obesity without diabetes: SURMOUNT-5

SURMOUNT-5 was an open-label phase 3b trial funded by Eli Lilly, which makes tirzepatide. It randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of either tirzepatide or semaglutide, taken once weekly for 72 weeks.

Weight: The least-squares mean weight change at week 72 was −20.2% with tirzepatide (95% CI −21.4 to −19.1) and −13.7% with semaglutide (95% CI −14.9 to −12.6).
Waist: Mean waist circumference change was −18.4 cm with tirzepatide and −13.0 cm with semaglutide.
Side effects: The most common adverse events in both groups were gastrointestinal. Most were mild to moderate and happened mainly while doses were being increased, though GI effects can be severe for some people.

(Aronne et al., NEJM 2025; PMID 40353578; DOI 10.1056/NEJMoa2416394.)

These are group averages from one trial population, not a prediction for any individual.

Type 2 diabetes: SURPASS-2

SURPASS-2 (Frías et al., NEJM 2021) was a 40-week open-label trial, also funded by Eli Lilly. It randomized 1,879 adults with type 2 diabetes to one of three tirzepatide doses or to semaglutide 1 mg once weekly.

Blood sugar (A1C): Mean A1C fell by 2.01 to 2.30 percentage points across the tirzepatide groups, compared with 1.86 points with semaglutide.
Weight: Across the tirzepatide groups, average weight reduction was 1.9 to 5.5 kg greater than with semaglutide.

(PMID 34170647; DOI 10.1056/NEJMoa2107519.)

An important caveat: the semaglutide dose in SURPASS-2 was lower than the highest doses now used for weight management, so this wasn’t a “maximum vs maximum” weight comparison.

How to read these numbers

Trial averages don’t tell you what will happen to you.
Diabetes status, starting weight, the dose reached, how long someone stays on treatment, and lifestyle all affect results.
Both trials were open-label and manufacturer-funded. That’s common for this kind of study, but worth knowing.
Higher-dose semaglutide options approved since these trials may change future comparisons. Our plain-English guide to the STEP, SURMOUNT, and SELECT trials puts these studies in context.

How do side effects compare?

The overlap is large. Common effects for both include nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion. Fatigue and injection-site reactions can also occur. In trials, GI effects clustered during dose increases and were often mild to moderate, but they can be severe, and they don’t always fade.

The labels for these products describe serious risks, including (not a complete list):

acute pancreatitis
gallbladder disease
kidney injury linked to dehydration
low blood sugar, especially with insulin or sulfonylureas
serious allergic reactions
a boxed warning about thyroid C-cell tumors seen in rodents (they’re contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2)

Because they slow stomach emptying, the labels also advise telling your healthcare team about any planned surgery or procedure that involves anesthesia or deep sedation.

Neither drug is gentle for everyone or harsh for everyone. Some people tolerate one better than the other.

What tends to shape the choice?

These are themes people often raise with their clinicians. They aren’t recommendations.

Labeled use: Does a specific indication apply, such as cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound), MASH (Wegovy), or type 2 diabetes (Ozempic, Rybelsus, Mounjaro)?
Trial evidence: How do the comparative results above line up with the goals under discussion?
Format: Is a weekly injection or a daily tablet more practical?
Practical factors: Coverage, out-of-pocket cost, other medications, pregnancy plans, GI history, and diabetes complications often matter as much as pharmacology.

What about shortages and compounded versions?

As of September 2026, FDA lists the national shortages of tirzepatide (resolved in late 2024) and semaglutide injection products (declared resolved February 21, 2025) as over, according to its compounding policy statement. FDA has said compounders generally may not make “essentially copies” of these commercially available drugs. Compounded drugs are not FDA-approved, and FDA doesn’t review them for safety, effectiveness, or quality before they’re sold. In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. That’s a proposal, not a final rule; the comment period closed July 30, 2026, and we found no final determination as of September 30, 2026.

Where to go next

See how the brand pairs differ: Wegovy vs Ozempic and Zepbound vs Mounjaro.
Put the big trials in context with our plain-English guide to the STEP, SURMOUNT, and SELECT trials.

Key takeaways

Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist.
Brand pairs share a molecule but not a label: Ozempic, Wegovy, and Rybelsus contain semaglutide; Mounjaro and Zepbound contain tirzepatide.
The injectable forms are typically once weekly, and their labels describe gradual dose increases. Your clinician determines the dose.
In SURMOUNT-5 (751 adults with obesity, no diabetes), average 72-week weight loss was −20.2% with tirzepatide vs −13.7% with semaglutide.
Side-effect profiles overlap heavily, and GI effects are the most common for both.

FAQ

Is tirzepatide stronger than semaglutide? “Stronger” isn’t a label term. In SURMOUNT-5, adults with obesity but without type 2 diabetes lost more weight on average with tirzepatide (−20.2%) than with semaglutide (−13.7%) over 72 weeks. That’s a trial average. Individual response, tolerability, and labeled use all vary, and a clinician weighs them case by case.

Can you switch from one to the other? People do switch, often because of side effects, coverage, supply, or a change in goals. There’s no FDA conversion chart that turns a dose of one drug into a dose of the other. The labels say combining these medicines with other GLP-1 receptor agonist products is not recommended, and combining semaglutide and tirzepatide hasn’t been established as safe, so any switch or overlap is the prescriber’s call. Timing and starting dose for any switch are for your prescribing clinician to decide.

Are Ozempic and Wegovy the same drug? They contain the same active ingredient, semaglutide, but they’re separate products with different labeled uses, dose strengths, and prescribing information. The same is true of Mounjaro and Zepbound, which both contain tirzepatide.

Is compounded semaglutide or tirzepatide the same as the brand-name drug? No. Compounded drugs aren’t FDA-approved, and FDA doesn’t check them for safety, effectiveness, or quality before they’re sold. As of September 2026, FDA considers the national shortages of both drugs resolved.

Are these medicines safe for everyone? No medicine is. Both carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. They also carry other warnings listed in their prescribing information.

This article is for general education and isn’t medical advice. Talk with a licensed clinician before starting, stopping, or changing any medication.

We may have a financial affiliation with some entities featured on this page.

References

Ozempic prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Rybelsus and Ozempic tablets prescribing information (DailyMed, revised 1/2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
Zepbound prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Wegovy prescribing information (DailyMed, injection and tablets): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Mounjaro prescribing information (FDA, 2026 label): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
FDA, policies for compounders as national GLP-1 supply stabilizes: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
FDA, proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (April 30, 2026): https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
Federal Register notice, May 1, 2026: https://www.federalregister.gov/documents/full_text/html/2026/05/01/2026-08552.html
Aronne et al., NEJM 2025 (SURMOUNT-5): PMID 40353578, DOI 10.1056/NEJMoa2416394
Frías et al., NEJM 2021 (SURPASS-2): PMID 34170647, DOI 10.1056/NEJMoa2107519